PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

PicoCELA Inc. (NASDAQ:PCLA) was the target of a significant growth in short interest in the month of May. As of May 29th, there was short interest totaling 126,693 shares, a growth of 1,375.2% from the May 14th total of 8,588 shares. Based on an average daily volume of 9,565,111 shares, the short-interest ratio is currently 0.0 days. Approximately 333.4% of the shares of the company are sold short.

Hedge Funds Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. Jane Street Group LLC purchased a new position in PicoCELA Inc. (NASDAQ:PCLA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned 18.92% of PicoCELA at the end of the most recent reporting period.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PicoCELA in a research report on Wednesday, April 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

PicoCELA Trading Up 2.7%

Shares of PCLA traded up $0.18 during mid-day trading on Wednesday, reaching $6.68. The stock had a trading volume of 4,856 shares, compared to its average volume of 833,078. PicoCELA has a 12 month low of $1.35 and a 12 month high of $112.20. The business has a fifty day moving average of $3.60 and a 200 day moving average of $5.15. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.57 and a current ratio of 2.13.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.